Literature DB >> 19179614

Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Yvonne M Schrage1, Liesbeth Hameetman, Karoly Szuhai, Anne-Marie Cleton-Jansen, Antonie H M Taminiau, Pancras C W Hogendoorn, Judith V M G Bovée.   

Abstract

The tumor suppressor genes EXT1 and EXT2 are involved in the formation of multiple osteochondromas, which can progress to become secondary peripheral chondrosarcomas. The most common chondrosarcoma subtype is primary central chondrosarcoma, which occurs in the medullar cavity of bone. The EXT1/EXT2 protein complex is involved in heparan sulfate proteoglycan (HSPG) biosynthesis, which is important for signal transduction of Indian hedgehog (IHH), WNT, and transforming growth factor (TGF)-beta. The role of EXT and its downstream targets in central chondrosarcomas is currently unknown. EXT1 and EXT2 were therefore evaluated in central chondrosarcomas at both the DNA and mRNA levels. Immunohistochemistry was used to assess HSPG (CD44v3 and SDC2), WNT (beta-catenin), and TGF-beta (PAI-1 and phosphorylated Smad2) signaling, whereas IHH signaling was studied both by quantitative polymerase chain reaction and in vitro. mRNA levels of both EXT1 and EXT2 were normal in central chondrosarcomas; genomic alterations were absent in these regions and in 30 other HSPG-related genes. Although HSPGs were aberrantly located (CD44v3 in the Golgi and SDC2 in cytoplasm and nucleus), this was not caused by mutation. WNT signaling negatively correlated with increasing histological grade, whereas TGF-beta positively correlated with increasing histological grade. IHH signaling was active, and inhibition decreased cell viability in one of six cell lines. Our data suggest that, despite normal EXT in central chondrosarcomas, HSPGs and HSPG-dependent signaling are affected in both central and peripheral chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179614      PMCID: PMC2665757          DOI: 10.2353/ajpath.2009.080623

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Order out of chaos: assembly of ligand binding sites in heparan sulfate.

Authors:  Jeffrey D Esko; Scott B Selleck
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

Review 2.  CD44: from adhesion molecules to signalling regulators.

Authors:  Helmut Ponta; Larry Sherman; Peter A Herrlich
Journal:  Nat Rev Mol Cell Biol       Date:  2003-01       Impact factor: 94.444

3.  Microvasculature and VEGF expression in cartilaginous tumors.

Authors:  G Ayala; C Liu; R Nicosia; S Horowitz; R Lackman
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

Review 4.  Cartilage proteoglycans.

Authors:  C B Knudson; W Knudson
Journal:  Semin Cell Dev Biol       Date:  2001-04       Impact factor: 7.727

5.  High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma.

Authors:  H J Baelde; A M Cleton-Jansen; H van Beerendonk; M Namba; J V Bovée; P C Hogendoorn
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

6.  Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.

Authors:  J V Bovée; L J van den Broek; A M Cleton-Jansen; P C Hogendoorn
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

7.  Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes.

Authors:  J V Bovée; R Sciot; P Dal Cin; M Debiec-Rychter; S L van Zelderen-Bhola; C J Cornelisse; P C Hogendoorn
Journal:  Diagn Mol Pathol       Date:  2001-12

8.  Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma.

Authors:  B Döme; B Somlai; A Ladányi; K Fazekas; M Zöller; J Tímár
Journal:  Virchows Arch       Date:  2001-11       Impact factor: 4.064

9.  Heparan sulphate proteoglycan expression in human primary liver tumours.

Authors:  T Roskams; R De Vos; G David; B Van Damme; V Desmet
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  20 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 2.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

3.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

4.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

5.  No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Authors:  Christianne M A Reijnders; Cathelijn J F Waaijer; Andrew Hamilton; Emilie P Buddingh; Sander P D Dijkstra; John Ham; Egbert Bakker; Karoly Szuhai; Marcel Karperien; Pancras C W Hogendoorn; Sally E Stringer; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

6.  In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.

Authors:  Camille Delaunay-Lemarie; Jean-Baptiste Vincourt; Béatrice Marie; Shyue-Fang Battaglia-Hsu; Stéphanie Etienne; François Sirveaux; Phi Linh Nguyen Thi; Jacques Magdalou; Jean-Michel Vignaud; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2015-06-23       Impact factor: 4.064

7.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes.

Authors:  Cathelijn J F Waaijer; Carlos E de Andrea; Andrew Hamilton; Jolieke G van Oosterwijk; Sally E Stringer; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2012-08-18       Impact factor: 4.064

8.  Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

Authors:  Annemiek van Maldegem; Anthony P Conley; Piotr Rutkowski; Shreyaskumar R Patel; Iwona Lugowska; Ingrid M E Desar; Judith V M G Bovée; Hans Gelderblom
Journal:  Oncologist       Date:  2018-08-06

9.  Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells.

Authors:  Fang Zong; Eleni Fthenou; Nina Wolmer; Péter Hollósi; Ilona Kovalszky; László Szilák; Carolin Mogler; Gustav Nilsonne; Georgios Tzanakakis; Katalin Dobra
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.